



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/056,528		
		Filing Date	January 23, 2002		
		First Named Inventor	Daryl W. HOCHMAN		
		Art Unit	1614		
		Examiner Name	Brian S. Kwon		
Sheet	1	of	1	Attorney Docket Number	48000.1003c2u

RECEIVED
FEB 04 2004
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-			
	2	US-			
	3	US-			
	4	US-			
	5	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country code ³ -Number ⁴ -Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	1	PARSONS, Andrew W., "Recent advances in mechanisms of spreading depression," <i>Current Opinion in Neurology</i> , Vol. 11, pp. 227-231 (1998)			
	2	SNOW, Robert W., et al., "Electrophysiological and Optical Changes in Slices of Rat Hippocampus During Spreading Depression," <i>Journal of Neurophysiology</i> , Vol. 50, No. 3, pp. 561-572 (September 1983)			
	3	WALZ, Wolfgang et al., "Intense Furosemide-Sensitive Potassium Accumulation in Astrocytes in the Presence of Pathologically High Extracellular Potassium Levels," <i>Journal of Cerebral Blood Flow and Metabolism</i> , Vol. 4, pp. 301-304 (1984)			
	4	KIMELBERG, H.K. et al., "Furosemide- and bumetanide-sensitive ion transport and volume control in primary astrocyte cultures from rat brain," <i>ABSTRACT - Brain Res.</i> , Vol. 361, Nos. 1-2, pp. 125-134 (Dec. 30, 1985)			
	5	KIMELBERG, H.K., "Anisotonic media and glutamate-induced ion transport and volume responses in primary astrocyte cultures," <i>ABSTRACT - J. Physiol. (Paris)</i> , Vol. 82, Nos. 4, pp. 294-303 (1987)			
	6	KEMPSKI, O. et al., "Glial ion transport and volume control," <i>ABSTRACT - Ann N.Y. Acad. Sci.</i> , Vol. 633, pp. 306-317 (1991)			
	7	WALZ, W., "Role of Na/K/Cl cotransport in astrocytes," <i>ABSTRACT - Can. J. Physiol. Pharmacol.</i> , Vol. 70, Suppl., pp. S260-S262 (1992)			
	8	WALZ, W., "Role of astrocytes in the spreading depression signal between ischemic core and penumbra," <i>ABSTRACT - Neurosci. Biobehav. Rev.</i> , Vol. 21, No. 2, pp. 135-142 (1997)			
	9	HOCHMAN, Daryl W., et al., "Extracellular Chloride and the Maintenance of Epileptiform Activity in Hippocampal Slices," <i>ABSTRACT - Society for Neuroscience</i> , Vol. 23, Part 2, p. 2425 (1997)			
	10	SINHA, S.R., et al., "Effects of Furosemide on Normal and Epileptiform Evoked Activity in Area CA1 of Guinea Pig Hippocampal Slice," <i>ABSTRACT - Society for Neuroscience</i> , Vol. 23, Part 2, p. 2425 (1997)			

Examiner Signature	<i>B.A.</i>	Date Considered	5-3-05
-----------------------	-------------	--------------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/056,528	
			Filing Date	January 23, 2002	
			First Named Inventor	Daryl W. HOCHMAN	
			Art Unit	1614	
			Examiner Name	Brian S. Kwon	
			Attorney Docket Number	48000.1003c2u	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-			
	2	US-			
	3	US-			
	4	US-			
	5	US-			
	6	US-			
	7	US-			
	8	US-			
	9	US-			
	10	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
		ROZEN, Todd D., MD, "Treatment of a prolonged migrainous aura with intravenous furosemide," <i>Neurology</i>, Vol. 55, pp. 732-733 (September 2000)		
4	2	COLLINS, Michael A., et al., "Brain damage due to episodic alcohol exposure in vivo and in vitro: furosemide neuroprotection implicates edema-based mechanism," <i>The FASEB Journal</i> , Vol. 12, pp. 221-230 (February 1998)		
	3	HOCHMAN, Daryl W., et al., "Dissociation of Synchronization and Excitability of Furosemide Blockade of Epileptiform Activity," <i>Science</i> , Vol. 270, pp. 99-102 (6 October 1995)		
	4	PINEGIN, L.E., et al., "Effect of furosemide on intracranial pressure in patients with intracranial hypertension," <i>ABSTRACT - Medline</i> (1983)		
	5	MISIUK, N.S., et al., "Effect of glycerol, mannitol and lasix on cerebrospinal fluid pressure in the acute period of a stroke," <i>ABSTRACT - Medline</i> (1981)		

Examiner Signature	Date Considered	P-30-05
--------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.